USSN: 10/743,109

- 22 -

PC20__2A

Remarks

Claims 1 – 50, as amended, and new claims 51 – 54 are pending in the application. The amendment to the specification and to claim 8 providing the definition of substituent X is supported in the specification and the claims as originally filed. For example, through a clerical error, the definition of substituent X was inadvertently omitted. However, it is clear from the context that the definition was meant to be X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4. Applicants point out that formulae II and III are clearly subsets of formula I. In formula I and formula III, X is defined as " $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4" whereas in formula II, the definition was inadvertently omitted. Applicants submit that the specification on page 22, line 9 and page 26, line 3, clearly supports these amendments to formula II and to claim 8. The amendment to claim 24 simply makes explicit what was already implicit in the claims, namely that the salts, hydrates, solvates, indeed any physical form of the compound is encompassed by the claims. New claims 51 – 54 were crafted by separating out the four structures presented in claim 24. Therefore, no new matter is presented.

In response to the Restriction Requirement under 35 U.S.C. §121 issued on October 2, 2006 in connection with above-captioned application, applicants hereby elect to prosecute the claims of Group I (claims 1-26 and 50) without traverse and further elect the species:

2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol;

which is specifically claimed as the second entry in Claim 24 and is further signified as "Compound A" on page 182 of the specification.

Claim 24, which specifically claims this compound, is independent; however, this compound is within the scope of Claim 1 and formula I as follows:

Z, at each occurrence, is CH2;

m, at each occurrence, is 3;

G is $(CH_2)_x$, wherein x is 2;

 W^1 and W^2 are each L, where L is $C(R^1)(R^2)$ - $(CH_2)_n$ -Y, wherein n is 1;

Y, at each occurrence, is OH; and

USSN: 10/743,109

- 23 -

PC20612A

X, at each occurrence, is $(CH_2)_z$, wherein z is 0.

Similarly, the compound falls within the scope of Claims 2-5 which are dependent upon Claim 1.

The elected compound also falls within the scope of Claim 8 and formula II as follows:

Z, at each occurrence, is CH2;

m, at each occurrence, is 3;

Q is $(CH_2)_x$, wherein x is 2;

 W^1 and W^2 are each L, where L is $C(R^1)(R^2)$ - $(CH_2)_n$ -Y, wherein n is 1;

Y, at each occurrence, is OH; and

X, at each occurrence, is (CH₂)_z, wherein z is 0.

Similarly, the compound falls within the scope of Claims 9 - 11, 13, 15, and 16 which are dependent upon Claim 8.

The elected compound also falls within the scope of Claim 17 and formula III as follows:

m, at each occurrence, is 3;

r is 2;

n is 1:

 R^1 , R^2 , R^{11} , and R^{12} are each methyl;

Y is OH; and

X, at each occurrence, is $(CH_2)_z$, wherein z is 0.

Similarly, the compound falls within the scope of Claim 18 which is dependent upon Claim 17.

As stated above, the elected compound also falls within the scope of Claim 24.

The elected compound is encompassed in Claim 50 as an allowed compound of any of Claims 1, 8, 17, or 24.

The elected compound is specifically claimed in new Claim 52.

Nov-02-2006 02:51pm From-Pfizer Info Mgmt

USSN: 10/743,109

- 24 -

PC20612A

On the basis of the above remarks, reconsideration of this application and its early allowance are respectfully requested.

Respectfully submitted,

Date: November 2 2006

William R. Boudreaux Reg. No. 35,796 2800 Plymouth Road Ann Arbor, MI 48105 Tel. (734) 622-1363 Fax (734) 622-2928